Key points are not available for this paper at this time.
Regulatory authorities, pharmaceutical companies, and clinicians need to agree on the most appropriate clinical endpoints for severe infections to ensure efficient approval of new, effective antibiotic agents.
Timsit et al. (Tue,) studied this question.